Usefulness of SynCAM3 and cyclin D1 immunohistochemistry in distinguishing superficial CD34-positive fibroblastic tumor from its histological mimics.

IF 1.2 4区医学 Q3 PATHOLOGY

Medical Molecular Morphology Pub Date : 2023-03-01 DOI:10.1007/s00795-022-00341-w

Shintaro Sugita, Tomoko Takenami, Tomomi Kido, Tomoyuki Aoyama, Michiko Hosaka, Keiko Segawa, Taro Sugawara, Hiromi Fujita, Yasutaka Murahashi, Makoto Emori, Atsushi Tsuyuki, Tadashi Hasegawa

{"title":"Usefulness of SynCAM3 and cyclin D1 immunohistochemistry in distinguishing superficial CD34-positive fibroblastic tumor from its histological mimics.","authors":"Shintaro Sugita, Tomoko Takenami, Tomomi Kido, Tomoyuki Aoyama, Michiko Hosaka, Keiko Segawa, Taro Sugawara, Hiromi Fujita, Yasutaka Murahashi, Makoto Emori, Atsushi Tsuyuki, Tadashi Hasegawa","doi":"10.1007/s00795-022-00341-w","DOIUrl":null,"url":null,"abstract":"<p><p>Superficial CD34-positive fibroblastic tumor (SCPFT) is a fibroblastic/myofibroblastic soft tissue tumor of rarely metastasizing intermediate malignancy. Some recent studies have described a relationship between SCPFT and PRDM10-rearranged soft tissue tumor (PRT) based on SynCAM3 and PRDM10 expression on immunohistochemistry. We performed CD34, cytokeratin AE1/AE3, SynCAM3, and PRDM10 immunohistochemistry in SCPFT and its histological mimics, including myxoinflammatory fibroblastic sarcoma (MIFS), superficially localized myxofibrosarcoma (MFS), and undifferentiated pleomorphic sarcoma. We also examined cyclin D1 expression because it is expressed in MIFS and MFS. We conducted fluorescence in situ hybridization (FISH) of PRDM10 rearrangement in SCPFT cases. On immunohistochemistry, only SCPFT showed strong and diffuse SynCAM3 expression. SCPFT also exhibited strong nuclear and weak cytoplasmic cyclin D1 expression, which was similar to that observed in MIFS. Two of five SCPFT cases exhibited nuclear PRDM10 expression. FISH revealed PRDM10 split signals in 44% and 24% of tumor cells in two SCPFT cases showing nuclear PRDM10 expression on immunohistochemistry, respectively. A minority of non-SCPFT cases showed focal SynCAM3 expression, but a combination of SynCAM3 and cyclin D1 in addition to CD34 and cytokeratin AE1/AE3 may be useful for the differential diagnosis of SCPFT and its histological mimics.</p>","PeriodicalId":18338,"journal":{"name":"Medical Molecular Morphology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Molecular Morphology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00795-022-00341-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Superficial CD34-positive fibroblastic tumor (SCPFT) is a fibroblastic/myofibroblastic soft tissue tumor of rarely metastasizing intermediate malignancy. Some recent studies have described a relationship between SCPFT and PRDM10-rearranged soft tissue tumor (PRT) based on SynCAM3 and PRDM10 expression on immunohistochemistry. We performed CD34, cytokeratin AE1/AE3, SynCAM3, and PRDM10 immunohistochemistry in SCPFT and its histological mimics, including myxoinflammatory fibroblastic sarcoma (MIFS), superficially localized myxofibrosarcoma (MFS), and undifferentiated pleomorphic sarcoma. We also examined cyclin D1 expression because it is expressed in MIFS and MFS. We conducted fluorescence in situ hybridization (FISH) of PRDM10 rearrangement in SCPFT cases. On immunohistochemistry, only SCPFT showed strong and diffuse SynCAM3 expression. SCPFT also exhibited strong nuclear and weak cytoplasmic cyclin D1 expression, which was similar to that observed in MIFS. Two of five SCPFT cases exhibited nuclear PRDM10 expression. FISH revealed PRDM10 split signals in 44% and 24% of tumor cells in two SCPFT cases showing nuclear PRDM10 expression on immunohistochemistry, respectively. A minority of non-SCPFT cases showed focal SynCAM3 expression, but a combination of SynCAM3 and cyclin D1 in addition to CD34 and cytokeratin AE1/AE3 may be useful for the differential diagnosis of SCPFT and its histological mimics.

Abstract Image

查看原文本刊更多论文

SynCAM3和细胞周期蛋白D1免疫组化在区分浅表cd34阳性纤维母细胞肿瘤及其组织模拟物中的作用。

浅表cd34阳性纤维母细胞瘤(SCPFT)是一种纤维母细胞/肌纤维母细胞软组织肿瘤，很少转移的中度恶性肿瘤。最近一些研究基于免疫组织化学SynCAM3和PRDM10的表达描述了SCPFT与PRDM10重排软组织肿瘤(PRT)之间的关系。我们对SCPFT及其组织模拟物进行了CD34、细胞角蛋白AE1/AE3、SynCAM3和PRDM10免疫组化，包括黏液炎性纤维母细胞肉瘤(MIFS)、浅表定位黏液纤维肉瘤(MFS)和未分化多形性肉瘤。我们还检查了cyclin D1的表达，因为它在MIFS和MFS中表达。我们对SCPFT病例的PRDM10重排进行了荧光原位杂交(FISH)。免疫组化显示，只有SCPFT表现出强烈且弥漫性的SynCAM3表达。SCPFT也表现出核强和细胞质弱的cyclin D1表达，这与MIFS相似。5例SCPFT中2例出现核PRDM10表达。FISH在两例SCPFT病例中分别在44%和24%的肿瘤细胞中显示PRDM10分裂信号，在免疫组织化学上显示核PRDM10表达。少数非SCPFT病例显示局灶性SynCAM3表达，但除了CD34和细胞角蛋白AE1/AE3外，SynCAM3和cyclin D1的联合表达可能对SCPFT及其组织学模拟物的鉴别诊断有用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical Molecular Morphology 医学-病理学

CiteScore

2.90

自引率

5.60%

发文量

审稿时长

>12 weeks

期刊介绍： Medical Molecular Morphology is an international forum for researchers in both basic and clinical medicine to present and discuss new research on the structural mechanisms and the processes of health and disease at the molecular level. The structures of molecules, organelles, cells, tissues, and organs determine their normal function. Disease is thus best understood in terms of structural changes in these different levels of biological organization, especially in molecules and molecular interactions as well as the cellular localization of chemical components. Medical Molecular Morphology welcomes articles on basic or clinical research in the fields of cell biology, molecular biology, and medical, veterinary, and dental sciences using techniques for structural research such as electron microscopy, confocal laser scanning microscopy, enzyme histochemistry, immunohistochemistry, radioautography, X-ray microanalysis, and in situ hybridization. Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.